Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

Autor: Smith, Jaclyn, McGarvey, Lorcan, Birring, Surinder, Hull, James, Carr, Warner W, Goldsobel, Alan B, Gross, Gary N, Holcomb, John R, Hussain, Iftikhar, Sher, Mandel, Spangenthal, Selwyn, Storms, William, Morice, Alyn, Elkayam, David, Steven, Gary C, Krainson, James, Fakih, Faisal Alfonso, Matz, Jonathan, Brooks, Gregory Daniel, Casale, Thomas, Berman, Gary D, Condemi, John J, Greos, Leon S, Gogate, Shaila U, Sher, Ellen R, Friesen, Jason H, Schenkel, Eric J, Bernstein, David Isaac, Corren, Jonathan, Sundar, Krishna, Gotfried, Mark H, Montanaro, Anthony, Lumry, William R, Amar, Niran J, Kaplan, Michael S, Prenner, Bruce M, Murphy, Thomas R, Good, James S, Parker, Sean, Harrison, Tim, Pavord, Ian, Brightling, Christopher, Djukanovic, Ratko, McQuaid, Douglas, Denenberg, Michael, Ettinger, Neil A, Iyer, Vivek, Smith, Jaclyn A ^*, Kitt, Michael M, Morice, Alyn H, Birring, Surinder S, McGarvey, Lorcan P, Sher, Mandel R, Li, Yu-Ping, Wu, Wen-Chi, Xu, Zhi Jin, Muccino, David R, Ford, Anthony P

Publikováno v: In The Lancet Respiratory Medicine August 2020 8(8):775-785

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Autor: Corte, Tamera, Glaspole, Ian, Holmes, Mark, Troy, Lauren, Veitch, Elizabeth, Bondue, Benjamin, Dahlqvist, Caroline, Louis, Renaud, Van Meerbeeck, Jan, Wuyts, Wim, Bittenglova, Radka, Kolek, Vitezslav, Pauk, Norbert, Reiterer, Pavel, Sterclova, Martina, Kilpeläinen, Maritta, Mäkitaro, Riitta, Myllärniemi, Marjukka, Purokivi, Minna, Rantala, Terhi, Cottin, Vincent, Couturaud, Francis, Israel-Biet, Dominique, Jouneau, Stéphane, Kessler, Romain, Lebargy, François, Marchand-Adam, Sylvain, Bollmann, Tom, Günther, Andreas, Hammerl, Peter, Kirschner, Joachim, Kirsten, Anne-Marie, Kreuter, Michael, Neurohr, Claus, Prasse, Antje, Schönfeld, Nicolas, Wiewrodt, Rainer, Attila, Somfay, Balazs, Medgyasszay, Csanky, Eszter, Losonczy, György, Hayashi, Hiroki, Homma, Sakae, Inoue, Yoshikazu, Izumi, Shinyu, Kitamura, Hideya, Nishioka, Yasuhiko, Nishiyama, Osamu, Ogura, Takashi, Okamoto, Masaki, Saito, Takefumi, Taniguchi, Hiroyuki, Zaizen, Yoshiaki, Filipowska, Marzena, Jarzemska, Agnieszka, Pierzchala, Wladyslaw, Piotrowski, Wojciech, Sladek, Krzysztof, Trawinska, Ewa, Kim, Young Whan, Park, Jong Sun, Song, Jin Woo, Aburto, Myriam, Castillo Villegas, Diego, Echave-Sustaeta, José María, Garcia Fadul, Christian, Herrera, Susana, Moises, Jorge, Molina-Molina, María, Moreno, Amalia, Nieto, Asunción, Rodríguez Nieto, María Jesús, Rodriguez-Portal, José Antonio, Safont, Belen, Sellares, Jacobo, Valenzuela, Claudia, Adamali, Huzaifa, Chaudhuri, Nazia, Gibbons, Michael, Hoyles, Rachel, Maher, Toby, Parfrey, Helen, Averill, Francis, Chambers, Steven, Ettinger, Neil, Giessel, Glenn, Jones, Lisa M, Kaye, Mitchell G, Oelberg, David, Westerman, Jan H, Zoz, Donald, III, Maher, Toby M ^*, Stowasser, Susanne, White, Eric S, Noth, Imre, Selman, Moisés, Rohr, Klaus B, Michael, Andreas, Ittrich, Carina, Diefenbach, Claudia, Jenkins, R Gisli

Publikováno v: In The Lancet Respiratory Medicine September 2019 7(9):771-779

OPEN-LABEL DOSE-ESCALATION DATA FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF PULSED, INHALED NITRIC OXIDE (INO) IN SUBJECTS AT RISK OF PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS (PH-PF) ON LONG TERM OXYGEN THERAPY

Autor: Nathan, Steven, Flaherty, Kevin, Raghu, Ganesh, Swigris, Jeffrey, Alvarez, Roger, Ettinger, Neil, Loyd, James, Fernandes, Peter, Gillies, Hunter, Shah, Parag, Lancaster, Lisa, Glassberg, Marilyn

Publikováno v: In Chest October 2019 156(4) Supplement:A2273-A2275

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide at a Dose of 30 μg/kg Ideal Body Weight/hr in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis Receiving Oxygen Therapy.

Autor: Nathan, Steven D., Flaherty, Kevin.R., Glassberg, Marilyn.K., Raghu, Ganesh, Swigris, Jeffrey, Alvarez, Roger, Ettinger, Neil, Loyd, Jim, Fernandes, Peter, Gillies, Hunter, Kim, Bo, Shah, Parag, Lancaster, Lisa

Publikováno v: CHEST; Aug2020, Vol. 158 Issue 2, p637-645, 9p